Skip to main content

Table 2 The proportion of patients on OAT were dispensed ADHD medication categorized on medical diagnoses and types of CAS

From: Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

a)
Year201520162017
All indications
Number of patients274312349
ADHD medicationNo.%aNo.%aNo.%a
Methylphenidate194712177020759
 - short- and intermediate-actingb182662066619355
 - long-actingc38143010339
Dexamphetamine632364216017
Atomoxetine238268216
Lisdexamphetamine14547158424
Racemic amphetamine<  50<  5182
b)
Year201520162017
ADHD
Number of patients223270312
ADHD medicationNo.%aNo.%aNo.%a
Methylphenidate171761987219462
 - short- and intermediate-actingb163731907018258
 - long-actingc32142610299
Dexamphetamine452055205317
Atomoxetine125197165
Lisdexamphetamine12539147223
Racemic amphetamine<  5<  5<  5<  572
  1. ADHD Attention deficit hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate, ICD-10 10th Revision of International Classification of Diseases, ICPC2 International Classification of Primary Care 2, and OAT opioid agonist therapy
  2. a Per cent of patients who received OAT and CAS, b Include all tablets and capsules with short- and intermediate-acting methylphenidate, c Include depot formulations of methylphenidate (Concerta®, Delmosart®, Equasym Depot®, or Methylphenidate Sandoz®)
  3. The tables display patients on OAT who were dispensed an ADHD medication in the period 2015 to 2017 categorized on a) all medical indications, and b) ADHD (ICD-10 code: F90 or ICPC2 code: P81)